Rejets radioactifs et environnement du CERN en 2004

La radioactivité de l’environnement autour de l’Organisation Européenne pour la Recherche Nucléaire (CERN) et les doses de rayonnements qui en résultent pour la population avoisinante sont contrôlées par la Commission de Sécurité du CERN et de manière indépendante par les autorités compétentes des deux États Hôtes, l’Institut de Radioprotection et de Sûreté Nucléaire (IRSN) côté France et l’Office Fédéral de la Santé Publique (OFSP) côté Suisse. Dans ce rapport, les résultats de mesures concernent en particulier le territoire suisse. L’ensemble des mesures effectuées en 2004 prouve que le fonctionnement des installations du CERN était sans conséquence radiologique sur l’environnement et la population. Le contrôle des émissions montre que les rejets effectifs se situent également en 2004 nettement en dessous des limites réglementaires. Ce constat est confirmé par le contrôle des immissions dans l’environnement. Le CERN a bien respecté en 2004 comme dans les années précédentes la valeur directrice de dose liée à la source fixée à 0.3 mSv/an. L’impact réel représente en fait moins de 5% de cette valeur, comme l’indique l’estimation pour le groupe de référence, qui est de l’ordre de 0.01 mSv/an

Surface moisture measurement system electro-magnetic induction probe surface irregularity tests

Surface irregularities cause the EMI moisture measurement to infer too low of a free water content in the HLW tank

PFP vertical calciner shield wall dose rate calculations using MCNP

This report yields a neutron shield wall design for a full time occupancy dose rate of 0.25 mrem/h. ORIGEN2 generated gamma ray spectrum and neutron intensity for plutonium. MCNP modeled the calciner glovebox and room for reflection of neutrons off concrete walls and ceiling. Neutron calculations used MCNP in mode n, p to include neutron capture gammas. Photon calculations used MCNP in mode p for gamma rays. Neutron shield with lower 137.16 cm (4.5 feet) of 12.7 cm (5 inch) thick Lucite{reg_sign} and 0.3175 cm (0.125 inch) stainless steel on both sides, and upper 76.2 cm (2.5 feet) of 10.16 cm (4 inch) thick Lucite{reg_sign} and 1.905 cm (0.75 inch) thick glass on each side gave a total weighted dose rate of 0.23 mrem/h, fulfilling the design goal. Lucite{reg_sign} is considered to be equivalent to Plexiglas{reg_sign} since both are methylmethacrylate polymers

The Second International Conference on Sentinel Node Biopsy in Mucosal Head and Neck Cancer

Background: The Second International Conference on Sentinel Node Biopsy in Mucosal Head and Neck Cancer was hosted by the Department of Otorhinolaryngology, Head and Neck Surgery of the University Hospital in Zurich, Switzerland, from September 12 to 13, 2003. The aims of this conference were to present the results of validation studies and to achieve a consensus on methodological requirements. Methods: More than 80 delegates from 20 countries attended the conference. The presented validation studies were summarized and compared with the literature. Consensus was achieved concerning requirements for lymphatic mapping and histopathologic work-up. Results: Twenty centers presented results on 379 patients with cN0 disease. Sentinel nodes were identified in 366 (97%) of 379. Of these 366, 103 (29%) were positive for occult metastasis, and 263 (71%) were negative. Of those 263 patients, 11 patients (4%) showed nodal disease not revealed by the sentinel lymph node biopsy (SNB). The negative predictive value of a negative sentinel node for the remaining neck was 96%. The consensus conference resulted in the use of a radiotracer, lymphoscintigraphy, and a handheld gamma probe for lymphatic mapping as minimal requirements. The use of conventional hematoxylin and eosin staining and immunohistochemistry for cytokeratin is mandatory. Step-sectioning of the entire node at intervals of 150μm is recommended. Conclusions: The conference attracted delegates from all over the world, thus underscoring the high interest in the topic. With regard to the presented data and the data from the literature, SNB for early oral and oropharyngeal cancer is sufficiently validated. The consensus conference resulted in the definition of minimal methodological requirements for accurate SN

Free triiodothyronine (T3) is negatively associated with fasting ghrelin serum levels in a population sample of euthyroid subjects

Purpose: Ghrelin is an orexigenic peptide hormone secreted in times of stress and hunger. It is deeply involved in the regulation of metabolism and energy homeostasis, promoting energy intake and inhibiting energy expenditure on a metabolic level. In this regard, it has in many ways antagonistic effect on the thyroid hormones, which increase metabolism and thus energy expenditure. While there is reasonable evidence of a negative association between ghrelin and hormones of the hypothalamic-pituitary-thyroid (HPT-) axis from studies in patients with thyroid dysfunction and small intervention studies, large-scale studies in healthy subjects are lacking. Therefore, we studied the relationship between total ghrelin serum levels and serum levels of the thyroid hormones in a large sample of euthyroid subjects. Methods: Total ghrelin, thyroid-stimulating hormone (TSH), free thyroxine (fT4) and free triiodothyronine (fT3) were determined after an overnight fast in 1666 subjects participating in a population-based cross-sectional study ('LIFE') including 10,000 adults. 1012 subjects were included in this analysis. Multiple linear regression analyses were performed. Results: FT3 was negatively associated with serum ghrelin; total sample: β = - 0.0001, p < 0.001; men: β = - 0.0002, p = 0.013; women: β = - 0.0001, p = 0.010, adjusted for age, BMI, alcohol consumption, serum levels of TSH and fT4 and smoking status. No associations were found between ghrelin serum levels and serum levels of fT4 or TSH. Conclusion: This is to date the largest study investigating the relationship between total serum ghrelin and thyroid hormones. The results point to a complex interaction and should initiate further research

Association between self-rating depression scores and total ghrelin and adipokine serum levels in a large population-based sample

Background: Ghrelin and the adipokines leptin and adiponectin have been suggested to be involved in mood and anxiety regulation and to be altered in affective disorders. However, studies investigating the association between ghrelin, leptin and adiponectin and depressive symptomatology are scarce but might contribute to a better understanding of their involvement in mood regulation. We thus aimed investigating the association between depressive symptomatology and total ghrelin as well as leptin and adiponectin serum levels in a large population-based sample. Methods: Total serum ghrelin, adiponectin and leptin levels were determined in 1666 subjects of a population-based cross-sectional study (“LIFE”). The Center for Epidemiological Studies Depression Scale (CES-D) and the Inventory of Depressive Symptoms – Self Rating (IDS-SR) were administered. Multiple linear regression analyses were conducted to examine the association between total serum ghrelin, leptin and adiponectin and the intensity of depressive symptoms. Results: In the total sample (n = 1,092), neither ghrelin nor leptin or adiponectin serum levels showed a significant association with CES-D or IDS-SR sum scores (N = 1,092) or in depressed/non-depressed subjects. Leptin serum levels showed a significantly positive association with IDS-SR sum scores in elderly men (≥60 years; β = 0.122, 95% CI: 0.009; 0.236; p = 0.035). Conclusion: Our study suggests that peripheral levels of ghrelin and adipokines in a cross-sectional study design might not be sufficient to measure their involvement in depression, suggesting that associations are more complex and multi-layered. Copyright © 2022 Wittekind, Kratzsch, Biemann, Mergl, Riedel-Heller, Witte, Villringer and Kluge

Rejets radioactifs et environnement du CERN en 2003

La radioactivité de l’environnement autour de l’Organisation Européenne pour la Recherche Nucléaire (CERN) et les doses de rayonnements qui en résultent pour la population avoisinante sont contrôlées par la Commission de Sûreté du CERN et de manière indépendante par les autorités compétentes des deux Etats Hôtes, l’Institut de Radioprotection et de Sûreté Nucléaire (IRSN) côté France et l’Office Fédéral de la Santé Publique (OFSP) côté Suisse. Dans ce rapport, les résultats de mesures concernent en particulier le territoire suisse. L’ensemble des mesures effectuées en 2003 prouve que le fonctionnement des installations du CERN était sans conséquence radiologique sur l’environnement et la population. Le contrôle des émissions montre que les rejets effectifs se situent également en 2003 nettement en dessous des limites réglementaires. Ce constat est confirmé par le contrôle des immissions dans l’environnement. Le CERN a bien respecté en 2003 comme dans les années précédentes la valeur directrice de dose liée à la source fixée à 0.3 mSv/an. L’impact réel représente en fait moins de 10% de cette valeur, comme l’indique l’estimation pour le groupe critique, qui est de l’ordre de 0.03 mSv/an

Inspiratory muscle warm-up does not improve cycling time-trial performance

Purpose: This study examined the effects of an active cycling warm-up, with and without the addition of an inspiratory muscle warm-up (IMW), on 10-km cycling time-trial performance

Computational prediction of protein subdomain stability in MYBPC3 enables clinical risk stratification in hypertrophic cardiomyopathy and enhances variant interpretation

PURPOSE: Variants in MYBPC3 causing loss of function are the most common cause of hypertrophic cardiomyopathy (HCM). However, a substantial number of patients carry missense variants of uncertain significance (VUS) in MYBPC3. We hypothesize that a structural-based algorithm, STRUM, which estimates the effect of missense variants on protein folding, will identify a subgroup of HCM patients with a MYBPC3 VUS associated with increased clinical risk. METHODS: Among 7,963 patients in the multicenter Sarcomeric Human Cardiomyopathy Registry (SHaRe), 120 unique missense VUS in MYBPC3 were identified. Variants were evaluated for their effect on subdomain folding and a stratified time-to-event analysis for an overall composite endpoint (first occurrence of ventricular arrhythmia, heart failure, all-cause mortality, atrial fibrillation, and stroke) was performed for patients with HCM and a MYBPC3 missense VUS. RESULTS: We demonstrated that patients carrying a MYBPC3 VUS predicted to cause subdomain misfolding (STRUM+, ΔΔG ≤ −1.2 kcal/mol) exhibited a higher rate of adverse events compared with those with a STRUM- VUS (hazard ratio = 2.29, P = 0.0282). In silico saturation mutagenesis of MYBPC3 identified 4,943/23,427 (21%) missense variants that were predicted to cause subdomain misfolding. CONCLUSION: STRUM identifies patients with HCM and a MYBPC3 VUS who may be at higher clinical risk and provides supportive evidence for pathogenicity